Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Mayne Pharma Group ( (AU:MYX) ) has issued an announcement.
Mayne Pharma’s Annual Report for 2025 highlights the company’s dedication to enhancing patient access to medications through innovation and accessibility. This commitment is expected to strengthen their market position and positively impact stakeholders by ensuring the availability of better and safer medicines.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group is a pharmaceutical company committed to improving patient access to life-enhancing medications. The company focuses on creating innovative, safe, and accessible medicines to meet the evolving needs of the global market.
Average Trading Volume: 287,045
Technical Sentiment Signal: Buy
Current Market Cap: A$475.3M
Find detailed analytics on MYX stock on TipRanks’ Stock Analysis page.